Incidence of Complications of Peripheral Venous Access in the Type 2 Diabetic Population

Sponsor
Hospital Universitari Vall d'Hebron Research Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT04499638
Collaborator
(none)
500
1
16.4
30.4

Study Details

Study Description

Brief Summary

Diabetes Mellitus type 2 (T2DM) is one of the most frequent metabolic diseases worldwide. It is expected that in 2035 around 600 million people will suffer from the disease. A recent systematic review has estimated that the direct annual cost of Diabetes worldwide treatments and care is over $ 827 billion and has been independently associated with nosocomial complications, thrombosis-like infections and prolonged admissions. In addition, it is estimated that up to 90% of patients in acute hospitals require a peripheral venous catheter which are associated at the same time with mechanical, infectious and thrombotic acute complications. Recently the emergence of new medium-sized peripheral devices (Midline®) and new peripheral central venous access catheters (PICC), which are more biocompatible, are opening new clinical possibilities with the aim of improving safety and comfort during treatment time and the reduction of associated complications.

With all this, a observational case-control study has been proposed in order to analyze the impact of T2DM disease and its associated complications on the patient requiring peripheral venous access. Furthermore investigators will consider if these new peripheral devices can be a remarkable benefit for these patients. This study will be carried out at the Vall d'Hebron University Hospital in Barcelona, Spain

Condition or Disease Intervention/Treatment Phase
  • Device: Peripheral vascular catheters

Detailed Description

This Prospective case-control study will be carry out with patients that will be admitted in the hospitalization areas of the Vall d'Hebron Hospital. All research data will be collected by the hospital's vascular access nursing team. Complications related to peripheral venous access (phlebitis, thrombosis, pain, erythema, extravasation) and the time of catheter replacement are the focus outcomes of the present study and possible differences between the control group and the sample population of the T2DM will be analyzed. General clinical and anthropometric data (age, sex, BMI, toxic habits,...), cause of admission, co-morbidities, and all variables related to diabetes (time of evolution, degree of glycemic control, treatment, and presence of chronic complications) will also be collected. If there are any significant differences, they will be related to the different risk factors associated with T2DM through association of different epidemiological variables. Furthermore in this hypothetical case, the research team would intend to develop and carry out molecular studies through analysis of blood and urine components, proteinomics and genetic studies.

Hypothesis:
  • T2DM is an independent risk factor for catheter-related complications.

  • The use of new vascular access devices (Midline, PICC) in patients with T2DM would be associated with a lower risk of catheter-related complications.

Main objective:
  • To assess the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients.

It is expected to colect information of N=500 samples, 250 control group (noT2DM subjects) and 250 study group (T2DM subjects). Due to previous experience, the sample proposed is totally acceptable

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
500 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Incidence of Complications of Peripheral Venous Access in the Type 2 Diabetic Population. Analysis of Risk Factors and Comparative Study of Two Peripheral Devices
Actual Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Jan 30, 2021
Anticipated Study Completion Date :
May 15, 2021

Arms and Interventions

Arm Intervention/Treatment
Non type 2 diabetic patient

Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered

Device: Peripheral vascular catheters
Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
Other Names:
  • Short canula, Midline, PICC
  • Diabetic type 2 patient

    Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered

    Device: Peripheral vascular catheters
    Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
    Other Names:
  • Short canula, Midline, PICC
  • Outcome Measures

    Primary Outcome Measures

    1. How is the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients [12 month]

      Rate of complications associated with catheters: thrombosis, infection, pain and skin reaction

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Peripheral venous access requirement >7 days

    • Administration of intravenous treatment

    Exclusion Criteria:
    • Peripheral venous access for urgent or life-threatening pathology

    • Acute psychiatric pathology

    • Impossibility of peripheral venous access through the upper limb (amputations, extensive burns, etc.)

    • History of venous thrombosis due to catheter less than 1 year

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Vall d'Hebron Research Institute-VHIR Barcelona Spain 08035

    Sponsors and Collaborators

    • Hospital Universitari Vall d'Hebron Research Institute

    Investigators

    • Study Director: Rafael Simó, Prof., Vall Hebron Research Institute-VHIR

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Hospital Universitari Vall d'Hebron Research Institute
    ClinicalTrials.gov Identifier:
    NCT04499638
    Other Study ID Numbers:
    • PR(AG)74/2020
    First Posted:
    Aug 5, 2020
    Last Update Posted:
    Nov 24, 2020
    Last Verified:
    Nov 1, 2020

    Study Results

    No Results Posted as of Nov 24, 2020